Introduction {#s1}
============

Heart failure (HF) is a major health problem worldwide, including in Japan. Unfortunately, patient outcomes remain poor, with a 5-year survival rate of approximately 50% \[[@R01]\]. In Japan, the number of outpatients with HF is expected to increase rapidly, and there will be an estimated 1.2 million HF patients in 2025 \[[@R02]\]. In addition, the number of Japanese HF patients aged 65 - 84 years will gradually increase until a peak in 2025. The elderly face various challenges besides cardiac dysfunction, such as impaired cognitive function, reduced capacity for physical exercise, family relations, the need for nursing care, etc. Although it is important for elderly patients to receive appropriate medications to treat HF, we need to assess the precise conditions in these patients, including cardiac function. In this report, we describe the application of a multifaceted assessment using eight different evaluations (the mean life expectancy in HF using the Seattle Heart Failure Model (SHFM) \[[@R03]\], the severity of dementia \[[@R04], [@R05]\], nutrition \[[@R06]\], medication adherence \[[@R07]\], biomarker \[[@R08]\], sociality \[[@R9]\], performance \[[@R10], [@R11]\] and comorbidity \[[@R12], [@R13]\]) in an elderly patient with HF.

Case Report {#s2}
===========

An 86-year-old male complained of dyspnea and lower-leg edema. He had had hypertension for decades and had undergone a stent graft procedure for abdominal aortic aneurysm. He had dyspnea at night and lower-leg edema for the preceding 4 days. Since these symptoms were sustained, he was admitted to our university hospital due to suspected acute decompensated HF. His level of consciousness was good. His height and body weight were 162 cm and 46.2 kg, respectively. Although his blood pressure was 154/72 mm Hg, other vital signs were normal (heart rate: 95 beats/min, regular; respiratory rate: 19 /min). Heart sounds showed systolic ejection murmur on the left border of the second intercostal sternum. Coarse crackles were noted in the bilateral lung fields. A 12-lead electrocardiogram showed normal sinus rhythm (77 beats/min), flat T wave and a QRS duration of 90 ms. With regard to biochemical parameters in blood, creatinine, troponin-I and coagulative functions were all normal, whereas the levels of white blood cell count (10,500/mL) and C-reactive protein (1.62 mg/dL) were elevated, along with the brain natriuretic peptide (BNP) (853 pg/mL). The levels of albumin (3.9 g/dL), creatine kinase (59 U/L) and hemoglobin (11.7 g/dl) in blood were decreased. Chest radiography showed cardiac dilatation (cardiothoracic ratio of 58%) ([Fig. 1a](#F1){ref-type="fig"}), and plural effusion and pulmonary congestion were observed. Echocardiography showed a left ventricular ejection fraction of 58%, and mild aortic valve stenosis and regurgitation. The patient started to receive furosemide 40 mg/day, benidipine 2 mg/day and candesartan 4 mg/day, and HF gradually became compensated. On day 14, the cardiothoracic ratio decreased to 45% and plural effusion and pulmonary congestion were improved ([Fig. 1b](#F1){ref-type="fig"}). Although he was classified as New York Heart Association (NYHA) IV on admission, he was NYHA II at discharge on day 15.

![Chest radiography on admission (a) and at discharge (b).](cr-08-339-g001){#F1}

We performed a multifaceted assessment using eight different evaluations at both admission and discharge ([Table 1](#T1){ref-type="table"}). The evaluations included the mean life expectancy in HF using the SHFM \[[@R03]\], the severity of dementia \[[@R04], [@R05]\], nutrition \[[@R06]\], medication adherence \[[@R07]\], biomarker (the level of BNP in blood) \[[@R08]\], sociality \[[@R9]\], performance \[[@R10], [@R11]\] and comorbidity \[[@R12], [@R13]\]. Each parameter was scored on a 5-point scale (excellent = 5 points; good = 4 points; fair (average) = 3 points; poor = 2 points; failure = 1 point; maximum total points of 40) (*F*ukuoka *U*niversity Heart *F*ailure *S*coring System, FUFS). The mean life expectancy according to SHFM \[[@R03]\] on admission and at discharge was 4.9 years (4 points) and 5.4 years (5 points), respectively ([Table 1A](#T1){ref-type="table"}) ([Fig. 2](#F2){ref-type="fig"}). The severity of dementia was assessed using revised Hasegawa's dementia scale (HDS-R) \[[@R04], [@R05]\], and the scores on admission and at discharge were 5 and 5 points, respectively ([Table 1B](#T1){ref-type="table"}) ([Fig. 2](#F2){ref-type="fig"}). Nutrition was assessed using mini-nutritional assessment (MNA) with some modification of scoring \[[@R06]\]; the value on admission (3 points) improved to 4 points at discharge ([Table 1C](#T1){ref-type="table"}) ([Fig. 2](#F2){ref-type="fig"}). The scores for medication adherence ([Table 1D](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}) \[[@R07]\] on admission and at discharge were 4 and 5 points, respectively ([Fig. 2](#F2){ref-type="fig"}). Although BNP levels ([Table 1E](#T1){ref-type="table"}) \[[@R08]\] decreased to 523 pg/mL at discharge, there was no change in the number of points assigned to the biomarker evaluation. There was no problem in sociality as assessed by the home care score (HCS) with some modification of scoring \[[@R9]\]; the scores at both admission and discharge were 5 ([Table 1F](#T1){ref-type="table"}) ([Fig. 2](#F2){ref-type="fig"}). Performance as assessed by a modified frailty index derived from the Canadian Study of Health and Aging (modified FI-CSHA) \[[@R10], [@R11]\] improved from 4 points on admission to 5 points at discharge ([Table 1G](#T1){ref-type="table"}) ([Fig. 2](#F2){ref-type="fig"}). There were no changes in the number of points assigned to comorbidity using the Charlson comorbidity index between admission and discharge ([Table 1H](#T1){ref-type="table"}) ([Fig. 2](#F2){ref-type="fig"}) \[[@R12], [@R13]\] because the patient had both pulmonary emphysema and prostate cancer. Overall, the total score improved from 28 to 32 points.

###### A Multifaceted Assessment Using Eight Different Evaluations (A-H)

  Score, points                                                                                             1 (failure)                        2 (poor)                      3 (fair)           4 (good)                    5 (excellent)
  --------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------------------- ------------------ --------------------------- ---------------------------------
  A. Prediction of survival in heart failure (HF) using the Seattle Heart Failure Model (SHFM)                                                                                                                              
    Mean life expectancy, years                                                                             \< 2                               ≥ 2 and \< 3                  ≥ 3 and \< 4       ≥ 4 and \< 5                ≥ 5
  B. Dementia                                                                                                                                                                                                               
    Score, points                                                                                           1                                  2                             3                  4                           5
    Revised Hasegawa's dementia scale (HDS-R), points                                                       ≤ 6                                7 - 12                        13 - 18            19 - 24                     25 - 30
  C. Nutrition                                                                                                                                                                                                              
    Score, points                                                                                           1                                  2                             3                  4                           5
    Mini-nutritional assessment (MNA), points                                                               ≤ 10                               \> 10 and \< 17               ≥ 17 and \< 21     ≥ 21 and \< 24              24 - 30
  D. Medication adherence                                                                                                                                                                                                   
    Score, points                                                                                           1                                  2                             3                  4                           5
    Adherence, points                                                                                       \< 30                              30 - 39                       40 - 49            50 - 59                     60 - 70
  E. Biomarker                                                                                                                                                                                                              
    Score, points                                                                                           1                                  2                             3                  4                           5
    Brain natriuretic peptide (BNP), pg/mL                                                                  \> 500                             200 - 500                     100 - 199          40 - 99                     \< 40
  F. Sociality                                                                                                                                                                                                              
    Score, points                                                                                           1                                  2                             3                  4                           5
    Home care score (HCS), points                                                                           ≤ 3                                4 - 6                         7 - 8              9 - 10                      \> 10
  G. Performance                                                                                                                                                                                                            
    Score, points                                                                                           1                                  2                             3                  4                           5
    Modified frailty index derived from the Canadian Study of Health and Aging (CSHA), frailty impression   Terminally - very severely frail   Severely - moderately frail   Moderately frail   Mildly frail - vulnerable   Managing well - well - very fit
  H. Comorbidity                                                                                                                                                                                                            
    Score, points                                                                                           1                                  2                             3                  4                           5
    Charlson comorbidity index, points                                                                      ≥ 6                                5                             3 - 4              1 - 2                       0

![A multifaceted assessment on admission (a) and at discharge (b).](cr-08-339-g002){#F2}

###### Medication Adherence Scale

                                                                                                                                        Points
  ------------------------------------------------------------------------------------------------------------------------------------- ---------
  A. Coordination with medical staff regarding medication                                                                               
    1) Regarding medicine, I can ask medical staff such as medical doctors without hesitation.                                          1 - 5
    2) Regarding medicine, I can share my previous treatment course with medical staff such as medical doctors.                         1 - 5
    3) Regarding medicine, I can share my thoughts and goals with medical staff such as medical doctors.                                1 - 5
  B. Aggressiveness in acquiring and using information about medication                                                                 
    4) I ask if there is something I do not know about my medication.                                                                   1 - 5
    5) I report side effects of medicines, allergic symptoms, and unusual symptoms.                                                     1 - 5
    6) I know about my medicines and why they are needed.                                                                               1 - 5
    7) I use approaches to continue taking my medicine (ingenuity in daily life, etc.)                                                  1 - 5
    8) I am looking for and using information necessary for my medicines.                                                               1 - 5
  C. Conviction regarding medication and degree of cooperation                                                                          
    9) I am convinced about the necessity of my medicines.                                                                              1 - 5
    10) The use of medicines is part of my life, like eating meals and brushing my teeth.                                               1 - 5
    11) My family members and other people offer no resistance to helping me, such as by making phone calls regarding my medications.   1 - 5
  D. Compliance with medication                                                                                                         
    12) Medication has been used for the indicated number of times or tablets over the last three weeks.                                1 - 5
    13) Medication has been used for the indicated time over the last three weeks.                                                      1 - 5
    14) I did not stop taking my medicines at my own discretion.                                                                        1 - 5
  Total points                                                                                                                          14 - 70

1 point: not applicable; 2 point: not very true; 3 point: neither agree nor disagree; 4 point: slightly true; 5 point: applies.

Discussion {#s3}
==========

We evaluated the precise conditions, including cardiac function, in an elderly patient with acute decompensated HF using a multifaceted assessment with eight different evaluations. Elderly patients more frequently experience comorbidities, frailty, polypharmacy and cognitive impairment, all of which can have a significant impact on clinical outcomes. Thus, patients require proper evaluation to best assess and plan their care needs.

In this patient, the total points using a multifaceted assessment improved from 28 to 32. Interestingly, the mean life expectancy (SHFM) improved with short-term care during hospitalization. Although nutrition (MNA), medication adherence and performance (modified FI-CSHA) each improved by only 1 point, these three factors are significantly associated with the prognosis in patients with HF according to previous reports \[[@R14]-[@R17]\]. A poor nutritional status as assessed using the controlling nutritional status score was significantly associated with inflammation and predicts poor outcomes in patients with HF \[[@R14]\]. Medication adherence and social support, both independently and in combination, predicted cardiac event-free survival in patients with HF \[[@R15]\]. A high prevalence of frailty has been reported in older patients with HF \[[@R16]\]. Increased frailty has been associated with an increased risk of falls, hospitalization, nursing home admission and mortality, with poorer outcomes \[[@R17]\]. In addition, although dementia and delirium are associated with worse clinical outcomes, including a longer duration of hospitalization and increased inpatient and 1-year mortality \[[@R18]\], and patients with HF who receive home-based rehabilitation services make significant improvements in activities of daily living \[[@R19]\], this patient did not have dementia or delirium and had a high HCS.

We also assessed comorbidities on admission and at discharge. Although we appropriately treated HF during hospitalization, there were no changes in the points assigned to comorbidity. Up to 75% of patients aged \> 65 years will have multiple chronic conditions that will impact HF management \[[@R20]\], and comorbidity is one of the strongest independent predictors of re-hospitalization and mortality \[[@R21]\]. Thus, we must consider caring for comorbidities during hospitalization. In addition, the mean life expectancy improved at discharge. The SHFM provides an accurate estimate of 1-, 2-, and 3-year survival with the use of easily obtained clinical, pharmacological, device, and laboratory characteristics \[[@R03]\]. Since SHFM does not include assessments of dementia, nutrition, medication adherence, sociality or performance, we also need to carefully evaluate these factors in addition to any therapies (both pharmacological and with the use of devices) and laboratory parameters.

The prevalence of HF with preserved ejection fraction (HFpEF) is increasing \[[@R22]\]. In the present case, LVEF was 58%, and we gave a diagnosis of HFpEF, probably due to HTN. Since HFpEF is a condition for which no treatment has been proven to alter clinical outcomes, it is important to evaluate the patient's condition. When patients with HFpEF were further categorized as having relatively low LVEF (HFrlEF; EF 40-60%) or relatively high LVEF (HFrhEF; EF ≥ 60%), the BNP level was shown to have prognostic value in HFrlEF, but not in HFrhEF \[[@R23]\]. The BNP level may also be important for predicting the prognosis in HF patients. Since there was no change in the number of points assigned to BNP and its level was still high at discharge, more aggressive treatment might be needed, even though this patient is very elderly.

Comprehensive cardiac rehabilitation (CR) has been shown to improve quality of life in addition to cardiac function in patients with HF \[[@R24]\]. This patient immediately started CR. CR may also improve the patient's condition using eight evaluations, even though CR was only performed about 2 weeks.

To the future, it is necessary to evaluate the usefulness of a multifaceted assessment strategy in clinical trial, and it may subsequently give appropriate therapies.

Conclusion {#s3a}
----------

We evaluated the precise conditions using a multifaceted assessment strategy in an elderly patient with HF. The strategy was useful for evaluating the patient's condition in this case.
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